Analyse the mechanism of choroidal neovascularization (CNV) induced by oxidized LDL receptor and develope the therapy against CNV
Analyse the mechanism of choroidal neovascularization (CNV) induced by oxidized LDL receptor and develope the therapy against CNV
批准号:
17591842
负责人:
TSUTSUI Junichiro
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
1.黄斑下手术中脉络膜新生血管膜中巨噬细胞的聚集。其中一部分是积极的免疫染色抗体对A类清道夫受体(SR-A)是重要的动脉粥样硬化。新生血管膜以外的视网膜相关性黄斑变性也含有SR-A阳性巨噬细胞。清道夫受体可能在脉络膜新生血管形成中起重要作用.在野生型和LOX-1基因敲除(LOX-1 KO)小鼠中制备激光诱导的脉络膜新生血管(CNV)实验模型。LOX-1 mRNA表达在暴露后被诱导。野生型小鼠的前体基质金属蛋白酶(MMPs)蛋白水平升高,MMPs被激活,而LOX-1基因敲除小鼠的MMPs前体蛋白水平降低,MMPs的激活被抑制。在野生型小鼠中,激光照射区域内的新生血管检出率为93%,但在LOX-1基因敲除小鼠中, 关于我们 下降了43%。提示LOX-1可能促进脉络膜新生血管的形成.为了评价给予3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(匹伐他汀)对CNV的作用,已知匹伐他汀抑制动脉粥样硬化中的高脂血症和斑块形成,在大鼠中建立激光诱导的CNV实验模型。匹伐他汀治疗的大鼠在激光照射区域的荧光泄漏显著减少。匹伐他汀治疗组CNV的面积和厚度均明显低于对照组。这表明治疗剂量的匹伐他汀有效地抑制了大鼠实验性CNV。为了筛选人眼内液中所含的蛋白质,应用蛋白质组学技术对白内障手术中手术切除的眼内液进行双向电泳分析。提取银染蛋白质点,采用基质辅助激光解吸电离飞行时间质谱和数据库检索进行鉴定。白蛋白、别白蛋白、转铁蛋白、载脂蛋白、维生素D结合蛋白、促甲状腺素转移蛋白和抗胰蛋白酶是人房水中的主要蛋白质。
英文摘要
1. Macrophage cells accumulated in choroidal neovascular membranes excised surgically during submacular operation. A portion of them was positively immunostained with antibodies against Class-A scavenger receptors (SR-A) that were important for aterosclerosis. Neovascular membranes other than Age-related macular degeneration also contained SR-A positive macrophage cells. It is possibile that scavenger receptors have an important role for the choroidal neovascularization.2. The experimental models of laser-induced choroidal neovascularization (CNV) were prepared in wild type and LOX-1 gene knockout (LOX-1 KO) mice. The expression of LOX-1 mRNA was induced after exposure. The protein level of precursor matrix metalloproteinases (MMPs) was increased and MMPs were activated in wild mice, but in LOX-1 KO mice, the expression of precursor MMPs and activation of MMPs were suppressed. In wild type mice neovascularity within the laser-exposed area was detected with 93 %, but in LOX-1 KO mice it … More was reduced with 43 %. These data suggest that LOX-1 may promote the choroidal neovascularization.3. To evaluate the effect of the administration of the 3-hydroxy-3-methylglutaryl co-enzyme A(HMG-CoA) reductase inhibitors (pitavastatin) on CNV, that was known to suppress hyperlipidemia and plaque formation in atherosclerosis, the experimental models of laser-induced CNV was created in rats. Pitavastatin-treated rats had significantly less fluorescence leakage in laser-exposed area. Both the area and the thickness of CNV in pitavastatin-treated rais were significantly reduced compared with control. These indicate that the therapeutic dose of pitavastatin effectively suppressed experimental CNV in rats.4. In order to screen the protein cotained in the human intraocular fluid, the proteomics analysis was applied to get the two-dimensional electrophoresis profile; from the aqueous humors excised surgically during cataract operations. The silver-staining protein spots were picked up and identified by matrix-a: sisted laser desorption/ionization time-of-flight mass spectrometry and data base searching. Alubmin, alloalubmin, transferrin, apolipoprotein, vitamin D binding protein, transthretin, and antitrypsin were major proteins in the human aqueous humors Less
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cell.
Rho 相关蛋白激酶抑制剂 Y-27632 可诱导培养的人小梁网细胞粘附、收缩和运动的改变。
DOI:
--
发表时间:
2006
期刊:
Experimental Eye Research 82
影响因子:
--
作者:
[Koga T, Koga T, Awai M, Tsutsui J, Yue BYJT, Tanihara H.]
通讯作者:
Tanihara H.
DOI:
10.1016/j.exer.2007.02.005
发表时间:
2007-06
期刊:
Experimental eye research
影响因子:
3.4
作者:
[N. Sagara;T. Kawaji;A. Takano;Yasuya Inomata;M. Inatani;M. Fukushima;H. Tanihara]
通讯作者:
N. Sagara;T. Kawaji;A. Takano;Yasuya Inomata;M. Inatani;M. Fukushima;H. Tanihara
Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cell
Rho 相关蛋白激酶抑制剂 Y-27632 可诱导培养的人小梁网细胞粘附、收缩和运动的改变
DOI:
--
发表时间:
2006
期刊:
Experimental Eye Research 82
影响因子:
--
作者:
[Koga T, Koga T, Awai M, Tsutsui J, Yue BYJT, Tanihara H]
通讯作者:
Tanihara H
Effect of pitavastatin on experimental choroidal neovascularization in rat
匹伐他汀对大鼠实验性脉络膜新生血管的影响
DOI:
--
发表时间:
期刊:
Experimental Eye Research (In press)
影响因子:
--
作者:
[Sagara N, Kawaji T, Takano A, Inomata Y, Inatani M, Fukushima M, Tanihara H]
通讯作者:
Tanihara H
国内基金
海外基金
登录
查看更多内容
LOX-1介导肺栓塞形成及分子机制研究
-
批准号:2025JJ80193
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:罗平
-
依托单位:
基于“脾统血濡脉”探讨健脾益气法调控LOX-1/SPP1/EGF通路驱动mtROS 预防AS分子机制研究
-
批准号:82305061
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:王莹
-
依托单位:
LOX-1介导GLS1琥珀酰化调控谷氨酰胺代谢重编程促进非酒精性脂肪性肝病的作用和机制研究
-
批准号:2023JJ20081
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:祝小云
-
依托单位:
基于NASH类器官模型的SQLE/Nrf2/LOX-1轴在动脉粥样硬化斑块形成与稳定性中的作用及机制研究
-
批准号:82370517
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:梁景岩
-
依托单位:
LOX-1介导脂质沉积在低氧肺动脉高压右心室重构中的作用及机制
-
批准号:82241025
-
项目类别:专项项目
-
资助金额:50.00万元
-
批准年份:2022
-
负责人:胡长平
-
依托单位:
LOX-1介导种植体周围炎炎性骨吸收的机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:张倩
-
依托单位:
GPX4通过下调LOX-1减少巨噬细胞泡沫化抑制动脉粥样硬化的研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:代小艳
-
依托单位:
外泌体源性LOX-1介导低氧肺动脉高压肺血管重构作用及机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:胡长平
-
依托单位:
C型凝集素LOX-1调控细胞自噬影响肿瘤发生的作用机制研究
-
批准号:32071272
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:汪澜
-
依托单位:
基于PPARα/miR-133b-5p/Lox-1信号探讨紫檀芪对阿霉素心脏毒性的心肌保护作用及机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:
-
依托单位: